Search 

Digital CSO

FEBICO (Far East Bio-Tec. Co., Ltd.) was established in 1976. We have three main business segments: New Drug Development, Diagnostic Reagents, and Dietary Supplement .
We develop an anti-virus platform, FEM, to develop potential drug candidates.
We focus on developments of botanical drugs and biologics to resolve the unmet medical needs such as inflammation diseases (lung injury, liver inflammation, liver fibrosis), hepatitis B, and herpes.

Since 1989, at ferropharma we are changing the health care market by cutting value chains to decrease cost of drug development and drug availability.
One of our brand, EMELEMA® - Making Latest Medicine Available – is what we believe in and what drives the best talent from around the globe to join us.  
Our aim is to be known as the company that increases patient access to generic and innovative medicine. We focus on building bridges between markets, stakeholders and patients. Collectively, we believe in finding the most fair, straight and reliable provider for the distribution of Active Pharmaceutical Ingredients (API), Finished Dosage Forms (FDF) and services. Thanks to our dedicated teams in Brazil, China, Germany, India and Malta, we are using manufacturing plants for high quality products, in the most efficient way. We direct our attention on novel delivery systems and the provision of EU registered and manufactured drugs..
We made quality our priority. The EMA, FDA and ANVISA standards for APIs and FDFs are our benchmarks that we fulfill.
We operate worldwide but our core markets are China, Latin America and the European Union.

Public trade pharmaceutical company

Bio pharmaceutical

Focus-X is a preclinical stage biotech company committed to the Discovery and development,, of personalized precision medicine fulfilling the unmet needs in cancer diagnosis and treatment. We are to release the true potential of radioligand therapy by leveraging our world class peptide drug discovery platform and joining force with top radiopharmaceutical partners.

focus on pharmacy

Fosun Hani Securities Limited is a wholly-owned subsidiary of Fosun International Limited (HKEx: 00656), a leading global investment group (Fosun Group).

Fosun Hani Securities is Fosun Group's integrated financial hub and primary investment arm in Hong Kong. Established in 1995, Fosun Hani Securities is a participant member of The Stock Exchange of Hong Kong Limited (Broker No. 0820 and 0829).

Fosunpharma is a leading healthcare group in China. It has built a strong root domestically and developed a global operation strategy. With pharmaceutical manufacturing and R&D being core business segment, together with strong presences in medical devices and diagnostics, healthcare services, pharmaceutical distribution and retail.